LU Bio announces a continued investment in Cytoguide ApS
Cytoguide has reported positive animal efficacy and safety data and based on this, LU Bio has completed its second tranche investment in CytoGuide. LU Bios total investment in CytoGuide so far is SEK 4,5 million and the position in the company after this second tranche is 14,3%.
Cytoguide develops drugs that target receptors on cells in pathological tissues for medical purposes. This is achieved by linking receptor-targeting compounds with registered drugs with known pharmacological effect. The present lead drug candidate directs to the specific receptor CD163, the most abundant transport receptor on macrophages. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases.
To read the full press release